Vertex’s new cystic fibrosis medicine could help extend the company’s market dominance, while Bristol Myers aims to capitalize on a more convenient formulation of its Opdivo immunotherapy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,